[Controlled study of gadobenate dimeglumine versus gadopentetate in breast tumor MR dynamic enhancement scanning].
To compare the differences in diagnosing breast lesions between gadobenate (Gd-DTPA) and gadopentetate dimeglumine (Gd-BOPTA) in MR dynamic enhancement scanning. Continuous collection patients because of breast lesions from General Hospital of Lanzhou Command PLA in August 2012 to December 2014. Fifty-three women with breast lesions detected by clinical touch or by X-ray mammography and ultrasound examination were included. The patients were randomly injected with equivalent dose of Gd-BOPTA or Gd-DTPA. Two dynamic enhanced scanning were performed on the 3.0 T MR scanner separated by 48 to 72 hours and eight phases were collected 25 seconds after the injection. Analysis was done double-blinded to find out the lesions, make differential diagnosis, and to compare with the histopathology. Among the 87 lesions diagnosed by postoperative pathological detection, more lesions were detected by Gd-BOPTA than by Gd-DTPA, 83/87 (95.4%) vs 69/87 (79.3%) (P < 0.01), respectively, the difference is statistically significant. In the detection of malignant lesions, the sensitivity was 96.3% and 76.3%, and the specificity was 78.1% and 68.7%, for Gd-BOPTA and Gd-DTPA, respectively. Gd-BOPTA was better for the detection of breast lesions and differential diagnosis of benign and malignant lesions than Gd-DTPA. Especially, Gd-BOPTA is obviously better than Gd-DTPA in detection of breast nodules, and the lesions with weak strengthening effect or located inconspicuously.